Orbis Medicines secured EUR 90 million in Series A funding to advance its pipeline of oral macrocycle drugs, nCycles, focusing on validated biologic targets.

Target Company Overview

Orbis Medicines is at the forefront of oral macrocycle drug discovery, setting the stage for a new era in pharmaceutical development. The company's innovative pipeline features next-generation oral macrocycle drugs, referred to as 'nCycles,' which target established biologic pathways with significant therapeutic potential. Historically, macrocycles have been challenging to administer orally due to their complex structures, but Orbis aims to overcome this obstacle through its advanced nGen technology platform.

With a commitment to delivering high-value alternatives to traditional biologic therapies, Orbis Medicines is focused on producing oral formulations that prioritize patient experience and broader healthcare adoption. The company's strategic initiatives are hallmarked by rigorous scientific exploration and validation of its drug candidates, with a clear emphasis on maximizing patient outcomes.

Industry Overview in Denmark

Denmark has emerged as a significant hub for life sciences and biotechnology, fostering a conducive environment for research and innovation. The country boasts a strong collaboration between academic institutions and industry players, c